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Introduction
Voltage-gated ion channels mediate cellular excitability and thereby play a central role in the function of nerve and muscle (1) . When excitable cells are stimulated, they give rise to a tissue-specific electrical response known as the action potential. The duration of the action potential is determined by the balance between inward currents that favor depolarization and outward currents that favor hyperpolarization of the surface membrane. In skeletal muscle and heart, abnormalities of cellular repolarization are now recognized as important factors in several hereditary and acquired human diseases. In a family of myotonic muscle disorders, specific mutations in the skeletal muscle soAddress correspondence to John H. Lawrence, M.D., Ross Receivedfor publication 13 February 1995 and accepted in revised form 21 April 1995. dium channel have been identified that impair inactivation of the sodium channel, delay repolarization, and underlie the repetitive electrical activity of muscle fibers (2) (3) (4) . The congenital long QT syndrome is characterized by prolonged action potentials, a lengthening of the QT interval on the surface electrocardiogram, and ventricular arrhythmias (5) . The long QT syndrome (LQT)' is genetically heterogeneous, with localization to three different chromosomes (6, 7) . Mutations in a putative potassium channel gene, HERG, cause the chromosome 7-linked form of LQT (8) , and mutations in the cardiac sodium channel gene, SCN5, cause the chromosome 3 -linked form of LQT (9) . In each of these diseases, the clinical phenotype reflects specific alterations in an ionic current that is active during the plateau phase of the action potential. In myocytes from hearts with nonhereditary cardiomyopathy, animal and human studies have consistently demonstrated a significant prolongation of action potentials compared with normal myocytes (10) (11) (12) . The delayed repolarization seen in these cells arises from a significant decrease in two potassium currents, the transient outward current and the inward rectifier (13, 14) . It has been hypothesized that the high incidence of sudden death in patients with heart failure is related to these altered membrane currents and an associated lability of cardiac repolarization (12) .
Genetic modification of membrane repolarization can be achieved by targeting the action potential plateau. During this time, membrane conductance is low, and even low levels of expression of heterologous ion channels would be capable of modulating the time course of repolarization (15) . Several methods potentially suitable for ion channel gene transfer to neurons and muscle have been reported (16) (17) (18) , including recombinant adenoviruses (19) (20) (21) (22) (23) (24) . Adenoviral vectors are particularly attractive for this application because they can transform a variety of post-mitotic cell types, multiply to very high titers, and incorporate inserts up to 8.1 kB (large enough for potassium, sodium or calcium channel genes) (25) (Fig. 1 a) . This plasmid, denoted pShK, was cotransfected with pJM17 into HEK293 cells using lipofectamine (Life Technologies, Gaithersburg, MD) (27) (RSV) promoter and a noninactivating tetraethylammonium (TEA)-sensitive Shaker potassium channel gene inserted into the viral early region 1 (El) by homologous recombination in HEK293 cells (Fig. 1 a) . El sequences include the viral transforming region that is necessary for viral DNA replication. HEK293 is a human embryonic kidney cell line transformed by sheared fragments of adenovirus serotype 5 that constitutively expresses adenoviral El gene products and allows propagation of replication-deficient adenoviruses (34) . We first sought evidence for adenovirus-mediated potassium channel expression in this cell line where AdShK can direct high levels of expression during a brief interval before cytopathic effects develop. A ribonuclease protection assay (RPA) performed on one 150 ml flask of HEK293 cells 24 h after infection with AdShK at a moi F 1 demonstrated a unique protected 466-bp RNA fragment from the 3' end of the gene insert (Fig. 1 b) (Fig. 1 c, middle) with kinetics that closely match recordings from Xenopus oocytes expressing this channel (26). Outward currents greater than 1 nA at +50 mV were seen in 30% of cells studied, consistent with the expected rate of plasmid-mediated transient transfection in these cells (35) . After infection with AdShK, we recorded outward currents similar in amplitude and kinetics to those seen following pShK transfection ( Fig. 1 c, right) . Outward currents greater than 1 nA in amplitude at +50 mV were observed in 12 of 12 cells from which currents were recorded, as expected since the virus freely replicates in HEK293 cells.
Modification of ionic currents and action potentials by AdShK in cardiac myocytes. Having established that AdShK directs high levels of expression in both permissive and nonpermissive cell lines, we next examined its effects in cultured heart cells. Cardiac myocytes were isolated from one-day-old neonatal rats, infected with AdShK (moi s 100) on day 1 or 2 in primary culture, and studied electrophysiologically on days 2 to 5. Depolarization to -40 mV elicited a robust inward sodium current confirming the identity of these cells as cardiac myocytes (Fig. 2 a) . Subsequent depolarization to +40 mV (Fig. 2 b) similar to those seen in AdShK-infected non-excitable cells.
Neonatal rat cardiac myocytes in primary culture exhibit intrinsic pacemaker activity (32, 33) , enabling us to record spontaneous action potentials. In control cells not infected with AdShK, characteristic cardiac action potentials were observed, and neither the duration nor the frequency of these action potentials was significantly altered by 5 mM TEA (Fig. 3, a and b,  left) . In contrast, action potentials from cells infected with AdShK exhibited a blunted plateau phase and a markedly abbreviated APDI50. These changes were reversibly blocked by 5 mM TEA (Fig. 3, a and b, right) , a concentration which blocks -90% of the current through this Shaker channel (26). The differences in action potential duration and in TEA-responsiveness illustrated in Fig. 3 a are representative and statistically significant. Pooled data from five uninfected control myocytes and six AdShK-infected myocytes confirmed the shortening of rate-corrected APDm at baseline in the AdShK group (Fig. 3 c). Stable impalements were maintained during the application and washout of 5 mM TEA in three cells from each group. The AdShK-infected cells exhibited a consistent increase in ratecorrected APD,50 during exposure to TEA (Fig. 3 d) , which was fully reversible (not shown); uninfected cells did not respond to TEA (Fig. 3 d) . Other action potential parameters showed less consistent differences or none at all. Spontaneous beating frequency was not different in uninfected (0.61±0.15 Hz; n = 5) vs. AdShK-infected myocytes (0.54±0.06 Hz; n = 6; p = 0.64), although it did increase during exposure to TEA in each of 3 AdShK-infected myocytes (from 0.51±0.08 Hz to 1.04±0.19 Hz; p = 0.06). Maximum diastolic potentials were variable in both groups (consistent with previous results from neonatal heart cells in primary culture; 32,33) but, on average, were not different in controls vs. AdShK-infected myocytes (-58±10 mV vs. -67±22 mV; p = n.s.).
In vivo expression of AdShK. Delivery of 107-108 pfu AdShK or AdLuc to l-d-old neonatal rats was achieved by a direct transthoracic injection into the heart. 2-4 d later, organs and tissues were harvested. Luciferase activity was detected in liver, heart, lung, skeletal muscle and brain (Fig. 4 a) . Although small, expression levels in the brain, lung and skeletal muscle were two to three orders of magnitude greater than background, while expression in the liver and heart were four to five orders of magnitude greater than background. Parallel experiments with a recombinant adenovirus expressing /3-galactosidase (Adfigal) revealed by visual inspection after transverse sectioning and staining that one-quarter to one-half of the fl-galactosidase activity resulted from direct myocardial injection along the needle track into the heart. Since our data and previous studies (19, 25, 30) using intravascular delivery of recombinant adenovirus have shown greatest levels of expression in the liver, we sought evidence for in vivo adenovirus-mediated expression of Shaker channels in this organ. From liver tissue harvested two to four days post-infection, an RPA confirmed expression of the Shaker mRNA (Fig. 4 b) . Whole-cell patch-clamp recordings revealed small outward currents (< 200 pA) in hepatocytes derived from AdLuc-infected rats (Fig. 4 c) , but much larger outward currents in hepatocytes isolated from AdShK-infected livers (Fig.  4 d) . The voltage-dependence of these currents matched that seen with in vitro AdShK infection (Fig. 1 d, 2 b) . However, the decay of current in response to strong depolarizations was consistently more rapid in hepatocytes than that observed in HEK293 or cardiac cells. These differences presumably reflect factors specific to each host cell (e.g., accessory proteins/subunits, changes in potassium channel heteromultimerization with such subunits, posttranslational modification, and/or endogenous gating modifiers).
Discussion
We have demonstrated that a replication-defective recombinant adenoviral vector directs expression of functional voltage-gated potassium channels following both in vitro and in vivo infection. AdShK replicates to high levels in HEK293 cells that complement the missing adenoviral El region and generates a large outward potassium current in this cell line. We also observed robust AdShK-mediated in vitro expression in nonpermissive cells, including 3T3 fibroblasts and rat neonatal cardiac myocytes. In each of these cell types, the kinetics and voltage- Fig. 1 We have observed that AdLuc widely disseminates after in vivo delivery into the arterial bloodstream with the greatest levels of expression occurring in the liver, consistent with other studies that have shown high levels of expression of reporter genes in the liver after peripheral administration of adenovirus (19, 25, 30) . Intravascular injection of AdShK results in expression of functional virally encoded potassium channels in the liver. While such an action may itself have subtle phenotypic consequences (hepatocyte membrane potential determines the rate of bile acid uptake [36] , for example), the most dramatic effects of ion channel overexpression would be expected in excitable tissues such as heart and brain.
Previous applications of viral gene transfer have as their ultimate goal either the correction of a defined genetic disorder (as in adenosine deaminase deficiency or cystic fibrosis) or the elaboration of potent paracrine or endocrine products (such as erythropoietin or tissue plasminogen activator; see reference 37 for a brief review). The ultimate goal of the present work is fundamentally different: we seek to modify the very phenotype of an end organ, an approach perhaps more analogous with pharmacologic therapy than with conventional gene therapy. The most obvious application, the reversal of genetic ion channel disorders, gives only the narrowest hint of potential therapeutic utility. Creative manipulation of ion channel composition in excitable tissues may be useful to treat disorders not only of excitation but also of contraction, secretion and transcription, all of which are modulated by the cell's complement of ion channels. Successful in vivo application of this technology will require improved delivery methods to achieve high and widespread levels of infection in organs other than the liver, incorporation of tissue-specific promoters to refine targeting of the gene product, and minimization of the virally induced inflammatory response (38) . Nevertheless, our results give good reason to expect that viral gene transfer represents a feasible and potentially powerful therapeutic strategy for the modification of excitability in vivo.
